Study Demonstrates Effectiveness of Stereotactic Body Radiation Therapy for Prostate Cancer

In a clinical study completed by a team of researchers in New York, CyberKnife® technology was used to determine how stereotactic body radiation therapy can improve disease control for prostate cancer. The results of more than 300 prostate cancer patients were examined in the short and long-term to measure toxicity and recurrence of cancer.

Results from patient follow ups detailed that no patients experienced advanced complications from treatment and PSA levels continued to fall steadily after treatment. The research team also noted CyberKnife’s noninvasive approach and ability to deliver treatment without anesthesia offered an advantage over other treatment options, such as high dose rate brachytherapy.

To read the full study, click here.

This is not intended as medical advice to replace the expertise and judgment of your health care team. It is intended to help you and your family make informed decisions, together with your doctor.